A Phase II, Open-label, Multiple-dose Trial to Investigate the Safety and Efficacy of UB-421 Monotherapy in Substitution for Stable Antiretroviral Therapy in HIV Infected Adults

Trial Profile

A Phase II, Open-label, Multiple-dose Trial to Investigate the Safety and Efficacy of UB-421 Monotherapy in Substitution for Stable Antiretroviral Therapy in HIV Infected Adults

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs UB 421 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors United BioPharma
  • Most Recent Events

    • 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections
    • 02 Aug 2016 Status changed from recruiting to completed.
    • 18 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top